Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.39 USD
+1.50 (1.27%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
Why You Should Add Surmodics (SRDX) to Your Portfolio Now
by Zacks Equity Research
Investor optimism is high on Surmodics (SRDX) stock, courtesy of its solid prospects.
Baxter (BAX) Receives FDA Nod for AK 98 Hemodialysis Machine
by Zacks Equity Research
Baxter (BAX) gets FDA approval for its AK 98 Hemodialysis machine that offers a compact, portable and easy-to-use system for dialysis providers.
Here's Why You Should Retain Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.
Quest Diagnostics (DGX) Inks Agreement to Enhance Cardiac Care
by Zacks Equity Research
Quest Diagnostics (DGX) signs agreement with Zora to develop cardiovascular mortality prediction test with the help of the latter's patented ceramide-analysis technology.
Luminex (LMNX) Files EUA Application for New Respiratory Assay
by Zacks Equity Research
Luminex (LMNX) develops the combined assay to rapidly deliver clear solutions about respiratory infections from a single test.
Here's Why You Should Retain Allscripts (MDRX) Stock for Now
by Zacks Equity Research
Investor confidence is high on Allscripts (MDRX) stock, courtesy of solid prospects.
Cardinal Health (CAH) Inks Deal to Divest Cordis Business
by Zacks Equity Research
Cardinal Health (CAH) divests its Cordis business to focus on strategic growth areas.
Here's Why You Should Retain AmerisourceBergen (ABC) Now
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches.
Is Abbott Laboratories (ABT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ABT) Outperforming Other Medical Stocks This Year?
Here's Why You Should Add McKesson (MCK) to Your Portfolio Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $117.52, moving +1.42% from the previous trading session.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio.
PerkinElmer (PKI) Boosts Testing Portfolio With New Solutions
by Zacks Equity Research
PerkinElmer's (PKI) introduction of two comprehensive solutions is likely to strengthen its COVID-19 testing portfolio further.
BD (BDX), ImageMover Partner for Rapid Antigen Test Reporting
by Zacks Equity Research
BD (BDX) collaborates with ImageMover to streamline rapid antigen testing results performed on the BD Veritor Plus System.
Intersect ENT (XENT) Q4 Loss Wider Than Expected, Revenues Top
by Zacks Equity Research
Intersect ENT's (XENT) sequentially rebound is strong on continued recovery in PROPEL, growth in SINUVA and initial sales of the company???s newly acquired Fiagon products.
Here's Why You Should Retain AMN Healthcare (AMN) Stock Now
by Zacks Equity Research
Investor optimism is high on AMN Healthcare (AMN) stock, courtesy of its solid prospects.
Abbott (ABT) Launches Telehealth Tool for Neuromodulation
by Zacks Equity Research
Abbott (ABT) stated that Medicare will cover remote programming services as a telehealth benefit through the duration of the public health emergency.
BD (BDX) Acquires GSL Solutions for Medication Management
by Zacks Equity Research
This acquisition should improve BD's (BDX) advanced medication management capabilities to further cater to the needs of retail pharmacies including those in outpatient settings.
Here's Why You Should Hold NextGen (NXGN) in Your Portfolio Now
by Zacks Equity Research
Investor optimism is high on NextGen (NXGN) stock, courtesy of its solid prospects.
Abbott's (ABT) Diagnostics Arm to Gain From New & Updated EUAs
by Zacks Equity Research
Abbott's (ABT) Alinity m SARS-CoV-2 test set to detect COVID-19 in individuals who do not have symptoms.
The Zacks Analyst Blog Highlights: Abbott, Johnson & Johnson, Masimo Corp and Medtronic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott, Johnson & Johnson, Masimo Corp and Medtronic
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $117.25, marking a +1.07% move from the previous day.
Cooper Companies (COO) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Cooper Companies' (COO) fiscal first-quarter earnings reflect solid segmental performance.
4 Stocks to Watch as FDA Action Plan Stresses MedTech Digitization
by Urmimala Biswas
These four MedTech stocks -- ABT, JNJ, MDT and MASI -- are expected to gain enormously from FDA's SaMD Action Plan 2021.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
Investor optimism is high on CONMED (CNMD) stock, courtesy of its solid prospects.